Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 mavorixafor trial in WHIM syndrome
NL-OMON54582Phase 3Recruiting
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mavorixafor in WHIM syndrome (WHIM) (3 arms), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Time above threshold absolute neutrophil count and Safety and tolerability. Started Jul 2021; status: recruiting.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NL-OMON54582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54582.